Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Alzheimer Disease

• Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
• ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
• A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
• A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
• Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
• Probiotics in Mild Alzheimer's Disease
• MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
• Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
• ACP-204 in Adults With Alzheimer's Disease Psychosis
• Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
• Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
• Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
• A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
• Phase II Clinical Trial of Interleukin-2 in AD
• Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
• Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
• COMMETS- Combination MCI Metabolic Syndrome
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease
• Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers
• An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
• Epileptic Hippocampus in Alzheimer's Disease
• A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
• Choline Effects - Pre-symptomatic AD
• [18F]MC225-PET in Neurodegenerative Disease
• Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
• CBD for Individuals at Risk for Alzheimer's Disease
• Low Dose IL2 Immunotherapy in AD
• Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers
• Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
• A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease
• Tricaprilin Phase 3 AD Study
• Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects
• A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
• Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration
• Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856
• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
• A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
• Nabilone for Agitation in Frontotemporal Dementia
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
• Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
• Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
• A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
• Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.
• Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease
• [18F]PI-2620 Phase 3 Histopathological Study
• Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management
• AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions
• A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
• Dronabinol for Agitation in Dementia Crossover Trial
• A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
• Innate Immunity Stimulation Via TLR9 in Early AD
• Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
• δ in Dementia Clinical Trials
• Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
• Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
• Open-label Extension for Phase 3 Clinical Trials of Simufilam
• Masitinib in Patients With Mild to Moderate Alzheimer's Disease
• rTMS for Apathy Clinical Trial
• A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
• IGC-AD1 Trial on Agitation in Dementia Due to AD
• [18F]APN-1607 PET in Subjects With AD Compared to HC
• Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease
• A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
• A Phase 3 Study of the Efficacy and Safety of AR1001 in Participants With Early AD
• A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
• Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
• Immunohistochemical Study of Neurodegenerative Diseases
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease Dementia
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
• Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
• A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease
• An Open-label Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease.
• Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
• Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.
• Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
• A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
• R21 Roche: 3-Way Tau Tracers in AD
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
• PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620
• Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
• Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease
• Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
• Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
• A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease
• A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects
• A Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Participants With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or Mild Alzheimer's Disease Dementia
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
• Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
• Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
• First-in-human Evaluation of EAAT2 PET Tracer in Healthy and Alzheimer's Diseased Brain
• Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients With Alzheimer's Disease
• Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
• Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
• A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
• A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
• Assess Fibrin in Brains With AD/ADRD
• SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
• ASURE: Alzheimer Study Using oRal Edaravone
• Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
• Study to Assess the Efficacy of XPro™ in Patients With Mild Alzheimer's Disease With Biomarkers of Inflammation
• Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
• A Study of Seltorexant in Participants With Probable Alzheimer's Disease
• GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
• A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
• Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
• Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease
• Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
• A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
• Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
• SCI-110 for Alzheimer Disease and Agitation
• Lomecel-B Effects on Alzheimer's Disease
• Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
• A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
• Phase II Open Label Study for the Use of Insulin-Sensitizer for Treatment of Cognitive Decline
• MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
• Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
• MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease
• GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
• Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
• Long-term Efficacy and Safety Study of GV-971
• Plasma P-tau2017 and Quantitative Amyloid PET Imaging
• Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
• Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
• Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
• A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
• The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
• SNIFF - Combo INI+EMPA Trial
• Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture
• Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
• Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease
• The Use of Memantine for Prevention of Alzheimer's Disease
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
• A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
• Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients
• Sirtuin-NAD Activator in Alzheimer's Disease
• Tricaprilin Liquid Formulation PK Study
• A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
• SNIFF - 3-Week Aptar CPS Device
• Aβ Dynamics in LLMD
• Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
• A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
• A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects
• A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
• Open-Label Safety Study of AXS-05 in Subjects With Alzheimer's Disease Agitation
• Dopaminergic Therapy for Frontotemporal Dementia Patients
• A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
• Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease
• Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
• Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
• Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
• The Synapse Project
• Effect of Hydralazine on Alzheimer's Disease
• Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease
• Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
• ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
• Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
• Senicapoc in Alzheimer's Disease
• A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
• Assessing Clinical Outcomes in Alzheimer's Disease Agitation
• Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia
• ALSENLITE: Senolytics for Alzheimer's Disease
• Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
• Efficacy and Safety of Yangxue Qingnao Pills in the Treatment of Mild to Moderate Alzheimer's Disease
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
• An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
• Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
• Long-term Effect of θ Burst Magnetic Stimulation on Clinical Symptoms of Alzheimer Disease
• Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
• A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects
• Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
• Telerehabilitation Alzheimer's Disease Feasibility (TADF)
• Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
• Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
• Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
• Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury
• Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
• Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
• A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127
• A Phase 3 Study of NE3107 in Alzheimer's Disease
• Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE)
• Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
• Sleep Trial to Prevent Alzheimer's Disease
• Rapamycin - Effects on Alzheimer's and Cognitive Health
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease
• Multimodal Biomarkers for Diagnosis and Prognosis in VCI
• A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
• Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
• A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
• A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
• Single Dose Study of ALZ-801 Prototype Tablets
• Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
• Exploratory Evaluation of [11C]MPC6827
• Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers
• Effect of CAFfeine on Cognition in Alzheimer's Disease
• Evaluation Comparing Two Tau PET Radiotracers, [18F]PI-2620 and [18F]GTP1, in Subjects With Normal Condition or Prodromal to Moderate Alzheimer's Disease
• Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
• Bryostatin Treatment of Moderately Severe Alzheimer's Disease
• Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
• Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
• Investigation of Inflammation Using [C-11]-CS1P1
• Nabilone for Agitation Blinded Intervention Trial
• Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
• A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
• A Translational Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
• ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
• Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
• A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
• Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyl
• Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
• Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• A Study to Compare the Pharmacokinetics of BR4002 and BR4002-1 in Healthy Volunteers
• A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
• Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
• Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
• Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
• GnRH Therapy on Cognition in Down Syndrome
• Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
• SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
• Amisulpride Treatment for BPSD in AD Patients
• A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
• OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
• To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
• The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
• MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
• Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
• Neuroinflammation in Alzheimer's Disease
• Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
• A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.
• Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
• The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease
• A Noval Tau Tracer in Young Onset Dementia
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
• BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease
• A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease
• Lymphatic System Health in Alzheimer's Disease
• Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
• Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
• A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
• Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
• Topography Staging and Dual Phase Image Quantification of Tau PET in Cognitive Impairment Subjects
• Multiple Ascending Dose Study of ALZ-801
• Study With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease
• Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
• Imaging Biomarkers in Preclinical and Symptomatic AD
• Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
• Cholinergic Health After Menopause (CHAMP)
• Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
• MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease
• Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
• Monitoring Anti-Dementia Drugs by Serum Levels
• Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
• Metformin in Alzheimer's Dementia Prevention
• Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
• PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
• Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia
• Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers
• Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease
• Senolytic Therapy to Modulate Progression of Alzheimer's Disease
• Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
• PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
• Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients
• MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
• A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
• Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)
• Montelukast Therapy on Alzheimer's Disease
• 11C-PIB PET Study in MESA at Columbia University
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
• Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
• Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production
• Multimodal Biomarkers for Diagnosis and Prognosis in CAA
• GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
• Deep Brain Stimulation for Alzheimer's Disease
• MAD Phase I Study to Investigate Contraloid Acetate
• SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate
• A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's
• A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects
• Tau Imaging With JNJ067
• A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
• A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
• Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
• Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers
• Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
• A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
• Treating Hyperexcitability in AD With Levetiracetam
• Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
• MRI and PET Biomarkers for Cognitive Decline in Older Adults
• Trial of Rifaximin in Probable Alzheimer's Disease
• A Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Participants and Participants With Prodromal Alzheimer's Disease (AD) to Moder
• The Efficacy of Traditional Chinese Herbal Medicine for Dementia
• Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
• Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
• Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
• Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects
• Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.
• A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.
• Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease
• UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
• Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
• A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
• Dapagliflozin In Alzheimer's Disease
• Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
• ANAVEX2-73 for Treatment of Early Alzheimer's Disease
• A Safety Study of PTI-125 in Healthy Volunteers
• A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
• Brain Imaging in the Diabetes Prevention Program Outcomes Study
• Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
• NMDA Enhancer for the Treatment of Mild Alzheimer's Disease
• A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
• PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
• Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
• Imaging Inflammation in Alzheimer's Disease With 11C-ER176
• Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
• Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
• A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
• An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
• Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults
• Prazosin for Agitation in Alzheimer's Disease
• Efavirenz for Patients With Alzheimer's Disease
• Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
• Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
• The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)
• A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers
• Interventions for Patients With Alzheimer's Disease and Dysphagia
• A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)
• The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
• A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalit
• Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides
• Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
• Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
• 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
• Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
• DHA Brain Delivery Trial
• Study of BHV-4157 in Alzheimer's Disease
• A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
• Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
• Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)
• Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
• A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine
• Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production
• A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
• Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
• Application of Amyloid PET in Cerebral Amyloid Angiopathy
• A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
• Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
• An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311
• Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
• A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
• Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
• A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
• UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
• Effect of CT1812 Treatment on Brain Synaptic Density
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
• An Investigation of Levetiracetam in Alzheimer's Disease
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
• Tau Screening Study in Subjects With Early Symptomatic AD
• A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
• Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
• Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
• Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)
• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
• Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia
• A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
• Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients
• A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations
• A Multiple Ascending Dose Study of COR388
• Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers
• Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
• Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease
• Imaging Tau in Alzheimer's Disease and Normal Aging
• PET Imaging of Subjects Using 124I-PU-AD
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
• Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
• Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
• Tau Screening Study in Patients With Early Symptomatic AD
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
• Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
• Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
• A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
• Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans
• Tau PET Imaging in Atypical Dementias
• Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease
• Anti-viral Therapy in Alzheimer's Disease
• F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected
• Salsalate in Patients Mild to Moderate Alzheimer's Disease
• A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol
• A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
• Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease
• Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
• Deferiprone to Delay Dementia (The 3D Study)
• Addressing Dementia Via Agitation-Centered Evaluation
• A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
• NP001, Alzheimer's Disease, and Blood Markers of Inflammation
• 2-HOBA for Prevention of Alzheimer's Disease
• A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease
• A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
• A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
• A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
• Noradrenergic Add-on Therapy With Guanfacine
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
• A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
• Escitalopram for Agitation in Alzheimer's Disease
• S-Equol in Alzheimer's Disease 2 Trial
• A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease
• Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
• A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain
• Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
• Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
• Z-Drugs for Sleep Disorders in Alzheimer's Disease
• Detecting an Early Response to Donepezil With Measures of Visual Attention
• Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
• Study of LM11A-31-BHS in Mild-moderate AD Patients
• Phase IIa L-serine Trial for eAD
• Nicotinamide as an Early Alzheimer's Disease Treatment
• Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
• Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
• Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
• Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)
• A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
• A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
• Study of Mirtazapine for Agitation in Dementia
• Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
• TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
• Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)
• A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
• Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
• Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
• Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease
• Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
• A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
• A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
• A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®
• A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
• Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
• A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
• Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
• Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
• Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations
• Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
• Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
• 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
• Risk Reduction for Alzheimer's Disease
• An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
• Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
• Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
• A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
• Imaging Tau in Alzheimer's Disease and Normal Aging
• A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
• I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD
• Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
• CPC-201 Alzheimer's Disease Type Dementia: PET Study
• A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
• The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression
• A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
• Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO
• Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
• Imaging Inflammation in Alzheimer's Disease
• A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
• ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
• Comparison of PET Amyloid Imaging in Japanese and Western Subjects
• Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05
• Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
• Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
• A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
• BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
• Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
• Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
• Implications for Management of PET Amyloid Classification Technology
• Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
• An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
• A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
• PET Imaging of Subjects Using 124I-PU-AD
• Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
• Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study
• A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
• Behavioral Expressions in Alzheimer's Disease
• Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
• DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil
• Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
• Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
• F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
• Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration
• NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
• Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia
• Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
• Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).
• Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
• Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
• Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
• [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
• Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease
• A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients
• BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
• Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
• Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
• HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease
• Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
• A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
• [11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
• A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
• Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
• 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
• Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
• 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
• Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
• Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
• An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
• [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
• Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
• Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
• Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients
• Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
• A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
• Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
• Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)
• Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)
• Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
• 18F-AV-1451 Autopsy Study
• Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
• BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)
• Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
• Health Evaluation in African Americans Using RAS Therapy
• Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease
• BAC in Patient With Alzheimer's Disease or Vascular Dementia
• Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
• Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease
• Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
• A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
• Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
• A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
• F 18 T807 Tau PET Imaging of Alzheimer's Disease
• F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)
• F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
• Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
• Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease
• Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease
• Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease
• Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
• A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.
• Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
• Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
• 24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion
• Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
• Rasagiline Rescue in Alzheimer's Disease Clinical Trial
• Investigating the Clinical Consequences of Flutemetamol-PET-scanning
• A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
• Safety and Efficacy of Nabilone in Alzheimer's Disease
• 18F-AV-1451 High Resolution Autopsy Study
• Apathy in Dementia Methylphenidate Trial 2
• Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function
• BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
• Augmenting Flortaucipir Dosimetry Estimates
• Safety Study of MT-4666 in Subjects With Alzheimer's Disease
• A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
• I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
• Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
• Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease
• An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
• Benfotiamine in Alzheimer's Disease: A Pilot Study
• Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
• Tau Imaging in Young Onset Dementia
• Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
• AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
• ATP in Alzheimer Disease
• Clinical Evaluation of Flortaucipir F 18
• Tau Imaging in Professional Fighters
• The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study
• A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease
• Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type
• Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type
• Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
• Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
• Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
• Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
• Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
• Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
• Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
• The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia
• A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
• A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.
• Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
• A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
• Longitudinal Study of Brain Amyloid imaGing in MEMENTO
• Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
• Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
• A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
• S-Equol in Alzheimer's Disease (SEAD) Trial
• Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
• Treatment of Psychosis and Agitation in Alzheimer's Disease
• A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
• Florbetapir Calibration to the Centiloid Scale
• The Feasibility of Florbetapir Quantitation in Europe
• Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
• DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia
• Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
• A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzhei
• Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
• Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
• Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
• Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
• Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
• Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
• Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
• Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles
• PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
• A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
• Evaluation of Reader Training Processes
• Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
• A Study of Gantenerumab in Participants With Mild Alzheimer Disease
• Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
• Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
• AZD3293 Thorough QT Study in Healthy Male Volunteers
• Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
• Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
• 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
• Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians
• A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease
• Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
• Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
• Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
• Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
• Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
• A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
• Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
• A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects
• A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
• GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
• Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
• Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
• A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease
• Effect of Insulin Sensitizer Metformin on AD Biomarkers
• Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
• n-3 PUFA for Vascular Cognitive Aging
• Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
• Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
• 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
• The Feasibility of Florbetapir Quantitation
• Zydena on Cognitive Function of Alzheimer's Disease Patients
• Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
• A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
• A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.
• Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
• The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
• Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
• Inhalational Anesthesia and Precipitation of Dementia: is There a Link?
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
• Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
• A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
• Study to Evaluate Coconut Oil for Alzheimer's Disease
• Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
• Masitinib in Patients With Mild to Moderate Alzheimer's Disease
• Mirtazapine for Sleep Disorders in Alzheimer's Disease
• Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
• A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
• A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects
• Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
• Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)
• Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
• Evaluating Liraglutide in Alzheimer's Disease
• Escitalopram for the Treatment of Depression in Alzheimer's Disease
• A Study of LY3002813 in Participants With Alzheimer's Disease
• Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
• PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
• Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
• Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
• Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease
• A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
• A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
• Bexarotene Amyloid Treatment for Alzheimer's Disease
• The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
• The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
• A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
• A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
• Safety and Efficacy of MT-4666
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Pro
• Bisnorcymserine in Healthy Adult Volunteers
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
• An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
• Long-Term Study of IGIV, 10% in Alzheimer´s Disease
• Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
• A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
• Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study
• Arterial Spin Labeling (ASL) MRI for Cognitive Decline
• A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
• Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
• Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
• An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
• Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
• Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
• Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
• Riluzole in Mild Alzheimer's Disease
• Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers
• A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers
• Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine
• Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
• Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
• Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
• This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
• Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
• A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
• Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
• A Study of Florbetapir (18F) in Japanese Healthy Volunteers
• Retrieval of Patient Information After Discontinuation
• A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
• Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia
• Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease
• Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
• Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study
• Efficacy and Safety of Filgrastim in Alzheimer's Disease
• Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
• Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
• Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults
• Delta-THC in Dementia
• Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
• Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase
• Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
• NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease
• Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
• Multicenter Vitamin E Trial in Aging Persons With Down Syndrome
• Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
• Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
• Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
• Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
• Evaluation of Physician Training Methods to Read Florbetapir-PET Scans
• Evaluation of PET Scan Timing Relative to AV-45 Injection Time
• A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
• A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
• A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
• A Study of 18F-AV-45 in Healthy Volunteers
• Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
• Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
• Seizure Activity in Alzheimer's Disease
• Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
• Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
• A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
• A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
• Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
• Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
• A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])
• Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
• Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
• Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
• A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
• Mirtazapine in Alzheimer-associated Weight Loss
• Resveratrol for Alzheimer's Disease
• A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
• A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])
• Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
• Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
• Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
• A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
• Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
• Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
• Identifying Potential Effects of Liraglutide on Degenerative Changes
• Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
• Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
• Minocycline in Patients With Alzheimer's Disease
• Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
• Optimisation of Antipsychotic Drug Use in Older People
• Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
• Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
• Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
• Endothelial Facilitation in Alzheimer's Disease
• Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
• Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
• A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
• VI-1121 for the Treatment Alzheimer's Disease
• Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
• Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
• Alzheimer's Disease - Input of Vitamin D With mEmantine Assay
• Cilostazol Augmentation Study in Dementia
• A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
• A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
• A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
• Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease
• Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease
• [18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
• Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
• 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
• Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
• Comparative Research of Alzheimer's Disease Drugs
• Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
• Trial of Carvedilol in Alzheimer's Disease
• Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
• Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers
• A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
• Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
• Alzheimer's Disease and Related Disorders
• Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients
• Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
• Imaging of Cognition, Learning, and Memory in Aging
• Pharmacokinetic Comparisons of Two Donepezil Formulations
• Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
• Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
• A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
• Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
• Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
• Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects
• A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease
• Study of STA-1 as an Add-on Treatment to Donepezil
• Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
• Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
• Multiple Dose Study of TRx0037
• Comparative Bioavailability in Healthy Elderly Volunteers
• Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
• A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
• An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
• Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers
• A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
• A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
• A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
• Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
• A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
• Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
• AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
• Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
• Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects
• Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
• Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
• Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
• The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
• Treatment of Apathy in Alzheimer's Disease With Modafinil
• Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients
• Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers
• An Extension of the CONCERT Protocol (DIM18)
• A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
• Effects of Simvastatin on Biomarkers
• Trazodone for Sleep Disorders in Alzheimer's Disease
• Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
• The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
• Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease
• A Safety Study of LY2886721 Single Doses in Healthy Subjects
• Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-
• Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
• Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
• To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
• Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
• Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease
• Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone
• Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.
• Apathy in Dementia Methylphenidate Trial (ADMET)
• Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
• Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163
• Alzheimer's Disease Acitretin Medication
• A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
• Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
• Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
• An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
• A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
• Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
• Multiple Dose Japanese Bridging Study
• Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease
• The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
• A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
• Bupropion for the Treatment of Apathy in Alzheimer's Dementia
• Drug-Drug Interaction Study With Aricept® (Donepezil)
• 4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
• Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
• Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers
• A Study of Semagacestat for Alzheimer's Patients
• Characteristics of Treatment Responders to Galantamine
• A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
• Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
• Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
• Exelon Patch and Combination With Memantine Comparative Trial
• The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
• Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
• Clinical Trial of Donepezil Between the Naive Group and the Switching Group
• Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
• Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease
• Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
• An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease
• Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine
• Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
• Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
• Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
• Drug-Drug Interaction Study With Rifampin
• Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
• A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
• A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
• To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden
• A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
• A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
• A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
• Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid
• Pioglitazone in Alzheimer Disease
• Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
• Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
• Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
• A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
• Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
• Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
• Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
• A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
• Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)
• Exploratory and Safety Study of [F-18]W372
• Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects
• Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease
• Imaging of Brain Amyloid Plaques in the Aging Population
• Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
• Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
• A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
• Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
• Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
• An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
• ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
• Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
• A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
• A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
• Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
• A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
• Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
• Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects
• Effect of LY2062430 on the Progression of Alzheimer's Disease
• Effect of LY2062430 on the Progression of Alzheimer's Disease
• Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
• Citalopram for Agitation in Alzheimer's Disease
• Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
• Non-Interventional Study With Aricept® Evess
• Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
• QTc Study of Rosi XR in Healthy Volunteers
• A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
• A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease
• A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
• Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
• A Safety and Tolerability Study of ABT-126 in Elderly
• Donepezil and Memantine in Moderate to Severe Alzheimer's Disease
• A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
• Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
• Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
• Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
• Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
• Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
• Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
• Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
• Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
• Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
• Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
• Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid
• A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
• A Safety Study of LY2811376 Single Doses in Healthy Subjects
• Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
• Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
• Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
• A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
• A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
• A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
• An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
• Zolpidem CR and Hospitalized Patients With Dementia
• Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
• Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
• A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
• Memantine and Validation of a New Alzheimer's Disease Scale
• Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease
• Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
• Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
• A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
• Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
• A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
• Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers
• Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
• A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
• Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
• Cerebral and Peripheral Perfusion Pilot Study
• Alzheimer and Sleep
• Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
• Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
• Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered
• Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease
• Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease
• A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
• PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers
• Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
• Drug Interaction Study With a Potential Alzheimer's Disease Compound
• Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531
• Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
• Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males
• Study GSI-136 in Healthy Young and Healthy Elderly Subjects
• A Pilot Study of Inflammatory Markers in Alzheimer's Disease
• Pharmacokinetic Interaction Between AZD3480 and Donepezil
• Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
• A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
• Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
• Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients
• Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
• Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
• Progression Delaying Effect of Escitalopram in Alzheimer's Disease
• A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
• Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease
• Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
• Drug Interaction Study Between AZD3480 and Cytochrome P450
• Drug Interaction Study Between AZD3480 and Warfarin
• Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
• Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects
• Open Label Study of TRx0014 in Alzheimer's Disease
• Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects
• A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
• Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
• A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
• Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease
• A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
• Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
• Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
• Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
• Memantine and Antipsychotics Use
• A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease
• Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
• A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes
• Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
• Rivastigmine in Mild Alzheimer's Disease, FMRI Study
• The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)
• Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
• Memantine - Communication Study
• A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
• Seroquel- Agitation Associated With Dementia
• Safety Study of CTS21166 to Treat Alzheimer Disease
• Metformin in Amnestic Mild Cognitive Impairment
• Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
• A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
• AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
• Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease
• Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
• Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
• Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
• Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
• The Impact of Lorazepam on Cognition in APOE e4 Carriers
• Effect of AQW051 in Patients With Memory Impairment
• Memory and Insulin in Early Alzheimer's Disease
• Safety Study of Nicotinamide to Treat Alzheimer's Disease
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
• The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease
• Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease
• A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
• Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin
• Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
• Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
• Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
• A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.
• Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
• Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
• Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
• The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease
• Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
• Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
• Hormone and Information Processing Study
• A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.
• Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)
• TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
• Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
• Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
• Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
• Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
• Study Evaluating the Effect of Lecozotan SR on the QTc Interval
• Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
• Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
• Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects
• Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
• Escitalopram and Depression in Elderly Alzheimer's Patients
• Evaluating Simvastatin's Potential Role in Therapy
• A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
• Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease
• The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients
• Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects
• Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
• Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males
• Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects
• Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
• Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults
• Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531
• Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males
• Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
• Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
• Neural Correlates In Mild Alzheimer's Disease
• Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
• Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315
• Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
• Development of NIC5-15 in the Treatment of Alzheimer's Disease
• Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
• A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.
• Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease
• PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)
• A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease
• Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
• A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
• Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
• Single Ascending Dose Study of SRA-444 in Healthy Subjects
• A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
• Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953
• DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease
• Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid
• Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
• SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)
• Effect of Indomethacin on the Progression of Alzheimer's Disease
• Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
• Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
• Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease
• Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
• MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
• Antipsychotic Discontinuation in Alzheimer's Disease
• GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
• Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
• Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease
• PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
• Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
• Memantine for Agitation and Aggression in Severe Alzheimer's Disease
• Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
• Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone
• Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease
• Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
• Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept
• The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
• Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
• Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
• Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
• Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
• Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients
• Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients
• Raloxifene for Women With Alzheimer's Disease
• Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects
• Study Evaluating PAZ-417 in Healthy Young/Elderly
• MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
• Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
• European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
• SB-742457 And Donepezil In Alzheimer's Disease
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
• Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
• Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
• Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
• Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
• Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
• A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
• Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
• Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
• A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
• Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
• Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
• Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease
• Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
• An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.
• Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
• An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period
• A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
• Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
• Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
• Study of the Effect of SR57667B in Patients With Alzheimer's Disease
• Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
• A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
• Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
• A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
• Escitalopram Treatment of Patients With Agitated Dementia
• Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
• The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
• Apathy Associated With Alzheimer's Disease
• A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
• Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
• Side Effects of Newer Antipsychotics in Older Adults
• Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease
• BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
• A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
• Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
• Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
• ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)
• EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
• Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia
• A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease
• An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
• European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
• Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
• The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
• A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease
• OmegAD (Omega-3 and Alzheimer's Disease)
• Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
• A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
• Alzheimer's Disease: Potential Benefit of Isoflavones
• TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
• TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
• Double Blind Study of Trp01 in Patients With Alzheimer's Disease
• Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease
• Donepezil Treatment of Psychotic Symptoms in Dementia Patients
• Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease
• Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
• Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients
• Alzheimer's Disease Long-term Follow-up Study (ALF Study)
• A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
• A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease
• Alzheimer's in Long-Term Care--Treatment for Agitation
• Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
• Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
• An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
• To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
• Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
• Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
• Tricaprilin in Mild to Moderate Alzheimer's Disease
• CALM-AD
• A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
• Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
• Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
• Anti-Oxidant Treatment of Alzheimer's Disease
• AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
• Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients
• Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
• Mifepristone as Adjunctive Therapy in Alzheimer's Disease
• Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
• Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
• Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
• Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease
• Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease
• Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
• An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
• Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
• Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
• The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
• Effect of Lithium and Divalproex in Alzheimer's Disease
• A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
• Depression in Alzheimer's Disease-2
• Huperzine A in Alzheimer's Disease
• Effects of ONO-2506PO in Patients With Alzheimer's Disease
• Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
• Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
• Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
• Valproate in Dementia (VALID)
• A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease
• Alzheimer's Disease: Therapeutic Potential of Estrogen
• Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease
• Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs
• ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
• Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
• Vitamin E in Aging Persons With Down Syndrome
• VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)
• Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study
• Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
• The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease
• Treatment for Early Memory Loss
• Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
• Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)
• Brain Imaging in Alzheimer's Disease
• Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
• A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease
• Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
• Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha
• Lipitor as a Treatment for Alzheimer's Disease
• Insulin, Neurogenetics and Memory in Alzheimer's Disease
• Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen
• Specific Interventions for Agitation in Alzheimer's Disease
• Electrophysiologic Measures of Treatment Response in Alzheimer Disease
• CATIE-Alzheimer's Disease Trial
• Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
• Effects of an Anti-Inflammatory Drug in Alzheimer's Disease
• Pain Management and Behavioral Outcomes in Patients With Dementia
• Ginkgo Biloba Prevention Trial in Older Individuals
• Treatment of Behavioral Symptoms in Alzheimer's Disease
• Serotonergic Pharmacotherapy for Agitation of Dementia
• The Depression in Alzheimer's Disease Study (DIADS)
• Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
• Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease
• The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
• A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)
• PET Scan of Brain Metabolism in Relation to Age and Disease
• Nefiracetam in the Treatment of Alzheimer's Disease
• Brain Imaging in Elderly People and Individuals With Alzheimer's Disease
• Treatment of Alzheimer's Disease With CX516 (Ampalex)
• Agitation in Alzheimer's Disease
• Multicenter Trial of Prednisone in Alzheimer's Disease
• Estrogen Hormone Protocol
• Alzheimer's Disease Prevention Trial
• Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
• Memory Impairment Study (Mild Cognitive Impairment Study)
• Evaluation of Galantamine in the Treatment of Alzheimer's Disease
• Study of Melatonin: Sleep Problems in Alzheimer's Disease